首页> 美国卫生研究院文献>Journal of Diabetes Investigation >Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized 52‐week open‐label parallel‐group trial

【2h】

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized 52‐week open‐label parallel‐group trial

机译：胰高血糖素样肽-1受体激动剂利拉鲁肽与口服降糖药联合使用在日本2型糖尿病患者中的安全性和有效性：一项随机52周开放标签平行组试验的事后分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims/IntroductionThe aim of the present post‐hoc analysis was to investigate the safety and efficacy of liraglutide in combination with one oral antidiabetic drug (OAD) across different OAD classes.

机译：目的/简介本事后分析的目的是研究利拉鲁肽与一种口服降糖药（OAD）联合用于不同OAD类型的安全性和有效性。

著录项

期刊名称 Journal of Diabetes Investigation
作者
Arihiro Kiyosue; Yutaka Seino; Keiji Nishijima; Heidrun Bosch‐Traberg; Kohei Kaku;
展开▼
作者单位

展开▼
年(卷),期 2018(9),4
年度 2018
页码 831–839
总页数 9
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Glucagon‐like peptide‐1 receptor agonist Liraglutide Type 2 diabetes;

机译：胰高血糖素样肽-1受体激动剂;利拉鲁肽;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial [J] . Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, Journal of diabetes investigation. . 2018,第4期

机译：胰高血糖素样肽-1受体激动剂利拉鲁肽与口服降糖药联合使用在日本2型糖尿病患者中的安全性和有效性：一项随机，52周，开放标签，平行组试验的事后分析
2. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial [J] . Arihiro Kiyosue, Heidrun Bosch-Traberg, Keiji Nishijima, Journal of diabetes investigation. . 2016,第1期

机译：利拉鲁肽与口服抗糖尿病药联合使用对日本2型糖尿病患者有效且耐受良好：一项随机，为期52周，开放标签，平行分组的试验
3. Long‐term safety and efficacy of the sodium–glucose cotransporter?2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type?2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study [J] . Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Journal of diabetes investigation. . 2019,第6期

机译：钠 - 葡萄糖Cot转储的长期安全性和功效？2抑制剂Tofogliflozin，在日本患者的胰高血糖素肽-1受体激动剂上添加了2型糖尿病：一个52周的开放标签，多中心，后营销临床研究
4. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized 52‐week open‐label parallel‐group trial [O] . Kohei Kaku, Arihiro Kiyosue, Yuri Ono, 2016

机译：利拉鲁肽与口服抗糖尿病药联合使用对日本2型糖尿病患者有效且耐受良好：一项随机为期52周开放标签平行分组的试验
5. Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial [O] . Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, 2017

机译：胰高血糖素的肽-1受体激动剂兴奋剂的安全性和疗效与日本2型糖尿病患者口腔抗糖尿病药物：随机，52周，开放标签，平行组试验的HOC分析

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized 52‐week open‐label parallel‐group trial

摘要

著录项

相似文献

相关主题

期刊订阅